April 5, 2012 - SK Capital Partners, a U.S. based private investment firm, and IBA (Ion Beam Applications S.A.) announced
that they have closed on their previously announced agreement to create IBA Molecular, a jointly-owned company derived from IBA’s worldwide radiopharmaceutical division. IBA Molecular is a worldwide leader in the manufacturing and distribution of radioactive isotopes used for medical imaging and therapy, with over 50 locations in the United States, Europe and Asia and employs over 1,000 people. The transaction is valued at approximately €180 million ($239 million). SK Capital will own 60 percent of the recapitalized entity and IBA will retain a 40 percent stake.
